Exelixis (EXEL) – Press Releases
-
Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
-
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
-
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
-
Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update
-
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February
-
Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU
-
Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024
-
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell
-
European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX® (cabozantinib) Tablets
-
Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024
-
Exelixis to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024
-
Exelixis 2023 R&D Day: Science & Strategy to be Webcast on December 12, 2023
-
Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head a
-
Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma
-
Exelixis to Present at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023
-
Exelixis Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023
-
Detailed Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023
-
Exelixis to Release Third Quarter 2023 Financial Results on Wednesday, November 1, 2023
-
Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor
-
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September
-
Exelixis Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors
-
Exelixis Announces Appointment of Amy Peterson, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer
-
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
-
Exelixis Announces Second Quarter 2023 Financial Results and Provides Corporate Update
-
Exelixis, Inc. Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc.
-
Exelixis to Release Second Quarter 2023 Financial Results on Tuesday, August 1, 2023
-
Farallon Capital Management Comments on Election of All Three of Its Nominees to Exelixis’ Board
-
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in June
-
Exelixis Announces First Quarter 2023 Financial Results and Provides Corporate Update
-
Farallon Capital Management Comments on Successful Campaign for Change at Exelixis
-
Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors
-
Exelixis to Present at the BofA Securities 2023 Healthcare Conference on May 10, 2023
-
Exelixis Files Definitive Proxy Statement and Mails Letter to Shareholders
-
Exelixis to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023
-
Exelixis Advances Board Refreshment Plan
-
Exelixis Reiterates Commitment to Shareholder Value Creation
-
Farallon Issues Letter to Exelixis Board of Directors Outlining Case for Change
-
Exelixis Announces $550 Million Share Repurchase Program
-
Exelixis to Webcast Fireside Chat at the 2023 Guggenheim Healthy Altitudes Summit
-
Exelixis Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Previously Treated Advanced Kidney Cancer
-
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
-
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
-
Exelixis and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors
-
Exelixis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
-
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February
-
Exelixis to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023
-
Exelixis Announces Update on Patent Litigation with MSN Laboratories
-
Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023
-
Nuvig Therapeutics Appoints Julie Smith Chief Executive Officer
-
Exelixis to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023 — Presentation to be webcast on www.exelixis.com —
Back to EXEL Stock Lookup
